Accessible Unlicensed Requires Authentication Published by De Gruyter April 1, 2014

Mechanisms of visceral pain in health and functional gastrointestinal disorders

Adam D. Farmer and Qasim Aziz

Abstract

Background and aims

Chronic visceral pain is common both in patients with identifiable organic disease and also in those without any structural, biochemical or immunological abnormality such as in the functional gastrointestinal disorders (FGIDs). We aim to provide a contemporaneous summary of pathways involved in visceral nociception and how a variety of mechanisms may influence an individual’s experience of visceral pain.

Methods

In this narrative review, we have brought together evidence through a detailed search of Medline in addition to using our experience and exposure to recent research developments from ourselves and other research groups.

Results

FGIDs are a heterogeneous group of disorders whose aetiology largely remains an enigma. The germane hypothesis for the genesis and maintenance of chronic visceral pain in FGIDs is the concept of visceral hypersensitivity. A number of peripheral and central mechanisms have been proposed to account for this epiphenomenon. In the periphery, inflammatory mediators activate and sensitize nociceptive afferent nerves by reducing their transduction thresholds and by inducing the expression and recruitment of hitherto silent nociceptors culminating in an increase in pain sensitivity at the site of injury known as primary hyperalgesia. Centrally, secondary hyperalgesia, defined as an increase in pain sensitivity in anatomically distinct sites, occurs at the level of the spinal dorsal horn. Moreover, the stress responsive physiological systems, genetic and psychological factors may modulate the experience of visceral pain. We also address some novel aetiological concepts in FGIDs, namely the gastrointestinal microbiota, connective tissue abnormalities and the gastrointestinal neuromuscular disorders. Firstly, the gastrointestinal microbiota is a diverse and dynamic ecosystem, that safeguards the host from external pathogens, aids in the metabolism of polysaccharides and lipids, modulates intestinal motility, in addition to modulating visceral perception. Secondly, connective tissue disorders, which traditionally have been considered to be confined largely to the musculoskeletal system, have an increasing evidence base demonstrating the presence of visceral manifestations. Since the sensorimotor apparatus of the GI tract is embedded within connective tissue it should not be surprising that such disorder may result in visceral pain and abnormal gut motility. Thirdly, gastrointestinal neuromuscular diseases refer to a heterogeneous group of disorders in which symptoms arise from impaired GI motor activity often manifesting as abnormal transit with or without radiological evidence of transient or persistent dilation of the viscera. Although a number of these are readily recognizable, such as achalasia or Hirschsprung’s disease, the cause in a number of patients is not. An international working group has recently addressed this “gap”, providing a comprehensive morphologically based diagnostic criteria.

Conclusions/implications

Although marked advances have been made in understanding the mechanisms that contribute to the development and maintenance of visceral pain, many interventions have failed to produce tangible improvement in patient outcomes. In the last part of this review we highlight an emerging approach that has allowed the definition and delineation of temporally stable visceral pain clusters, which may improve participant homogeneity in future studies, potentially facilitate stratification of treatment in FGID and lead to improvements in diagnostic criteria and outcomes.


Wingate Institute of Neurogastroenterology, 26 Ashfield Street, London E1 2AJ, UK. Tel.: +44 02078822648; fax: +44 02078825640

  1. Conflict of interest

    Conflict of interest statement: None of the authors have any conflict of interests to declare.

References

[1] Drossman DA. Rome III: the functional gastrointestinal disorders. McLean, VA: Degnon Associates; 2006. Search in Google Scholar

[2] Leadley RM, Armstrong N, Lee YC, Allen A, Kleijnen J. Chronic diseases in the European Union: the prevalence and health cost implications of chronic pain. J Pain Palliat Care Pharmacother 2012;26:310–25. Search in Google Scholar

[3] European Federation of IASP chapters. European Year Against Pain 2012 – Visceral Pain. http://www.efic.org/index.asp?sub=F8AMLHLAP9216P&topicsid=256 [accessed 14.12.13]. Search in Google Scholar

[4] Holschneider DP, Bradesi S, Mayer EA. The role of experimental models in developing new treatments for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2011;5:43–57. Search in Google Scholar

[5] Sikandar S, Dickenson AH. Visceral pain: the ins and outs, the ups and downs. Curr Opin Support Palliat Care 2012;6:17–26. Search in Google Scholar

[6] Blackshaw LA, Gebhart GF. The pharmacology of gastrointestinal nociceptive pathways. Curr Opin Pharmacol 2002;2:642–9. Search in Google Scholar

[7] Blackshaw LA, Brierley SM, Hughes PA, Harrington AM. The hot mustard receptor’s role in gut motor function. Gastroenterology 2011;141:423–7. Search in Google Scholar

[8] Aziz Q, Botha C, Willert R. Pharmacology of visceral pain: central factors. Dig Dis 2009;27(Suppl. 1):31–41. Search in Google Scholar

[9] Anand P, Aziz Q, Willert R, van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol Motil 2007;19:29–46. Search in Google Scholar

[10] Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009;141:191–209. Search in Google Scholar

[11] Tillisch K, Mayer EA. Pain perception in irritable bowel syndrome. CNS Spectr 2005;10:877–82. Search in Google Scholar

[12] Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011;140:91–100. Search in Google Scholar

[13] Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004;18:613–31. Search in Google Scholar

[14] Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643–50. Search in Google Scholar

[15] Saito YA, Talley NJL, Fett JM, Zinsmeister S, Locke ARGR. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil 2003;15:687–94. Search in Google Scholar

[16] Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569–80. Search in Google Scholar

[17] Yu S, Ouyang A. TRPA1 in bradykinin-induced mechano-hypersensitivity of vagal C fibers in guinea pig esophagus. Am J Physiol Gastrointest Liver Physiol 2009;296:G255–65. Search in Google Scholar

[18] Jones III RC, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci 2005;25:10981–9. Search in Google Scholar

[19] Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008;57:674–83. Search in Google Scholar

[20] Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 2007;132:615–27. Search in Google Scholar

[21] Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta 2007;1772:989–1003. Search in Google Scholar

[22] Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816–24. Search in Google Scholar

[23] Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 2004;500:231–41. Search in Google Scholar

[24] Akbar A, Walters JR, Ghosh S. Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. Aliment Pharmacol Ther 2009;30:423–35. Search in Google Scholar

[25] Banerjee B, Medda BK, Lazarova Z, Bansal N, Shaker R, Sengupta JN. Effect of reflux-induced inflammation on transient receptor potential vanilloid one (TRPV1) expression in primary sensory neurons innervating the oesophagus of rats. Neurogastroenterol Motil 2007;19:681–91. Search in Google Scholar

[26] Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923–9. Search in Google Scholar

[27] Gomes RB, Brodskyn C, de Oliveira CI, Costa J, Miranda JC, Caldas A, Valenzuela JG, Barral-Netto M, Barral A. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. J Infect Dis 2002;186:1530–4. Search in Google Scholar

[28] Othman AA, Nothaft W, Awni WM, Dutta S. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials. J Clin Pharmacol 2012;52:1028–41. Search in Google Scholar

[29] Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simren M, Funch-Jensen P, Drewes AM. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011;33:1113–22. Search in Google Scholar

[30] Quiding H, Jonzon B, Svensson O, Webster L, Reimfelt A, Karin A, Karlsten R, Segerdahl M. TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. Pain 2013;154:808–12. Search in Google Scholar

[31] Vergnolle N. Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol 2004;141:1264–74. Search in Google Scholar

[32] Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 2001;22:146–52. Search in Google Scholar

[33] Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 2007;21:103–13. Search in Google Scholar

[34] Vergnolle N. Postinflammatory visceral sensitivity and pain mechanisms. Neurogastroenterol Motil 2008;20(Suppl. 1):73–80. Search in Google Scholar

[35] Asfaha S, Cenac N, Houle S, Altier C, Papez MD, Nguyen C, Steinhoff M, Chapman K, Zamponi GW, Vergnolle N. Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br J Pharmacol 2007;150:176–85. Search in Google Scholar

[36] Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000;356:1154–9. Search in Google Scholar

[37] Sarkar S, Hobson AR, Hughes A, Growcott J, Woolf CJ, Thompson DG, Aziz Q. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 2003;124:18–25. Search in Google Scholar

[38] Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Tache Y, Wood JD. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006;130:1391–411. Search in Google Scholar

[39] Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-d-aspartate receptor. Gastroenterology 2004;126:683–92. Search in Google Scholar

[40] Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14:125–32. Search in Google Scholar

[41] Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, Schuster MM. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98:1187–92. Search in Google Scholar

[42] Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40–52. Search in Google Scholar

[43] Lemann M, Dederding JP, Flourie B, Franchisseur C, Rambaud JC, Jian R. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci 1991;36:1249–54. Search in Google Scholar

[44] Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987;93:727–33. Search in Google Scholar

[45] Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price DD. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003;103:99–110. Search in Google Scholar

[46] Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci 2001;46:2542–8. Search in Google Scholar

[47] Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980;25:404–13. Search in Google Scholar

[48] Nasr I, Attaluri A, Coss-Adame E, Rao SS. Diagnostic utility of the oesophageal balloon distension test in the evaluation of oesophageal chest pain. Aliment Pharmacol Ther 2012;35:1474–81. Search in Google Scholar

[49] Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002;51:410–3. Search in Google Scholar

[50] Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol 2011;26(Suppl. 3):94–101. Search in Google Scholar

[51] Garg AX, Macnab J, Clark W, Ray JG, Marshall JK, Suri RS, Devereaux PJ, Haynes B, Walkerton Health Study. Long-term health sequelae following E. coli and campylobacter contamination of municipal water. Population sampling and assessing non-participation biases. Can J Public Health 2005;96:125–30. Search in Google Scholar

[52] Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651–9. Search in Google Scholar

[53] Han W, Wang Z, Lu X, Guo C. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome. Neurogastroenterol Motil 2012;24:113–9, e82. Search in Google Scholar

[54] van Wanrooij SJ, Wouters MM, Van Oudenhove L, Vanbrabant W, Mondelaers S, Kollmann P, Kreutz F, Schemann M, Boeckxstaens GE. Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity? Am J Gastroenterol 2014;109:99–109. Search in Google Scholar

[55] Wilder-Smith CH. The balancing act: endogenous modulation of pain in functional gastrointestinal disorders. Gut 2011;60:1589–99. Search in Google Scholar

[56] Mikocka-Walus A, Turnbull D, Moulding N, Wilson I, Andrews JM, Holtmann G. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. J Gastroenterol Hepatol 2008;23:1137–43. Search in Google Scholar

[57] Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770–98. Search in Google Scholar

[58] Tyler K, Moriceau S, Sullivan RM, Greenwood-van Meerveld B. Long-term colonic hypersensitivity in adult rats induced by neonatal unpredictable vs predictable shock. Neurogastroenterol Motil 2007;19:761–8. Search in Google Scholar

[59] Elsenbruch S, Rosenberger C, Bingel U, Forsting M, Schedlowski M, Gizewski ER. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010;139:1310–9. Search in Google Scholar

[60] Leserman J, Drossman DA. Relationship of abuse history to functional gastrointestinal disorders and symptoms: some possible mediating mechanisms. Trauma Violence Abuse 2007;8:331–43. Search in Google Scholar

[61] Barreau F, Ferrier L, Fioramonti J, Bueno L. New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res 2007;62:240–5. Search in Google Scholar

[62] Alander T, Heimer G, Svardsudd K, Agreus L. Abuse in women and men with and without functional gastrointestinal disorders. Dig Dis Sci 2008;53:1856–64. Search in Google Scholar

[63] Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, Read NW. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150–3. Search in Google Scholar

[64] Saito YA, Zimmerman JM, Harmsen WS, De Andrade M, Locke 3rd GR, Petersen GM, Talley NJ. Irritable bowel syndrome aggregates strongly in families: a family-based case–control study. Neurogastroenterol Motil 2008;20:790–7. Search in Google Scholar

[65] Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799–804. Search in Google Scholar

[66] Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596–604. Search in Google Scholar

[67] Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, Ducker SJ, Muriithi AW, Wheater EF, Hammond CJ, Dawwas MF, UP Consortium, Wellcome Trust Case Control Consortium, Jones DE, Peltonen L, Peltonen L, Peltonen L, Peltonen L. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011;43:329–32. Search in Google Scholar

[68] Jones MP, Dilley JB, Drossman D, Crowell MD. Brain–gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006;18:91–103. Search in Google Scholar

[69] Tillisch K, Mayer EA, Labus JS, Stains J, Chang L, Naliboff BD. Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 2005;54:1396–401. Search in Google Scholar

[70] Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol 2006;2:90–8. Search in Google Scholar

[71] Mazurak N, Seredyuk N, Sauer H, Teufel M, Enck P. Heart rate variability in the irritable bowel syndrome: a review of the literature. Neurogastroenterol Motil 2012;24:206–16. Search in Google Scholar

[72] Keszthelyi D, Troost FJ, Masclee AA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G141–54. Search in Google Scholar

[73] Chua YC, Ng KS, Sharma A, Jafari J, Surguy S, Yazaki E, Knowles CH, Aziz Q. Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers – a placebo-controlled study. Aliment Pharmacol Ther 2012;35:319–26. Search in Google Scholar

[74] Sharma A, Paine P, Rhodes S, Warburton F, Chua YC, Aziz Q. The autonomic response to human esophageal acidification and the development of hyperalgesia. Neurogastroenterol Motil 2012;24:e285–93. Search in Google Scholar

[75] Paine P, Kishor J, Worthen SF, Gregory LJ, Aziz Q. Exploring relationships for visceral and somatic pain with autonomic control and personality. Pain 2009;144:236–44. Search in Google Scholar

[76] Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007;39:201–15. Search in Google Scholar

[77] Drossman DA. What does the future hold for irritable bowel syndrome and the functional gastrointestinal disorders? J Clin Gastroenterol 2005;39:S251–6. Search in Google Scholar

[78] Wingenfeld K, Heim C, Schmidt I, Wagner D, Meinlschmidt G, Hellhammer DH. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom Med 2008;70:65–72. Search in Google Scholar

[79] Farmer AD, Kano M, Coen SJ, Navqi H, Furlong PL, Scott SM, Knowles CH, Lightman S, Aziz Q. Psychophysiological responses to oesophageal stimulation in functional chest pain: a case control study. Neurogastroenterol Motil 2014;26:139–48. Search in Google Scholar

[80] Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, O’Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130:304–11. Search in Google Scholar

[81] Montiel-Castro AJ, Gonzalez-Cervantes RM, Bravo-Ruiseco G, Pacheco-Lopez G. The microbiota–gut–brain axis: neurobehavioral correlates, health and sociality. Front Integr Neurosci 2013;7:70. Search in Google Scholar

[82] Bercik P. The microbiota–gut–brain axis: learning from intestinal bacteria? Gut 2011;60:288–9. Search in Google Scholar

[83] Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science 2005;308:1635–8. Search in Google Scholar

[84] Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010;156:3205–15. Search in Google Scholar

[85] Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, Group TS. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22–32. Search in Google Scholar

[86] Simren M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG, Rome Foundation C. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159–76. Search in Google Scholar

[87] Jeffery IB, O’Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Simren M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012;61:997–1006. Search in Google Scholar

[88] Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dore J, Meta HITC, Antolin M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Merieux A, Melo Minardi R, M’Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winograd-sky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. Nature 2011;473:174–80. Search in Google Scholar

[89] Aziz Q, Dore J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 2013;25:4–15. Search in Google Scholar

[90] Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126–39, quiz 1-2. Search in Google Scholar

[91] Davis MP. The opioid bowel syndrome: a review of pathophysiology and treatment. J Opioid Manag 2005;1:153–61. Search in Google Scholar

[92] Farmer AD, Ferdinand E, Aziz Q. Opioids and the gastrointestinal tract – a case of narcotic bowel syndrome and literature review. J Neurogastroenterol Motil 2013;19:94–8. Search in Google Scholar

[93] Zarate N, Farmer AD, Grahame R, Mohammed SD, Knowles CH, Scott SM, Aziz Q. Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link? Neurogastroenterol Motil 2010;22:252–78. Search in Google Scholar

[94] Zeitoun JD, Lefevre JH, de Parades V, Sejourne C, Sobhani I, Coffin B, Hamonet C. Functional digestive symptoms and quality of life in patients with Ehlers–Danlos syndromes: results of a national cohort study on 134 patients. PLoS ONE 2013;8:e80321. Search in Google Scholar

[95] Hakim A, Keer R, Grahame R. Hypermobility, fibromyalgia and chronic pain. Edinburgh: Churchill Livingstone; 2010. Search in Google Scholar

[96] Mohammed SD, Lunniss PJ, Zarate N, Farmer AD, Grahame R, Aziz Q, Scott SM. Joint hypermobility and rectal evacuatory dysfunction: an etiological link in abnormal connective tissue? Neurogastroenterol Motil 2010;22:1085–283. Search in Google Scholar

[97] Knowles CH, De Giorgio R, Kapur RP, Bruder E, Farrugia G, Geboes K, Gershon MD, Hutson J, Lindberg G, Martin JE, Meier-Ruge WA, Milla PJ, Smith VV, Vandervinden JM, Veress B, Wedel T. Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group. Acta Neuropathol 2009;118:271–301. Search in Google Scholar

[98] Knowles CH, De Giorgio R, Kapur RP, Bruder E, Farrugia G, Geboes K, Lindberg G, Martin JE, Meier-Ruge WA, Milla PJ, Smith VV, Vandervinden JM, Veress B, Wedel T. The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut 2010;59:882–7. Search in Google Scholar

[99] Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013;25:453–7. Search in Google Scholar

[100] Edwards RR. Individual differences in endogenous pain modulation as a risk factor for chronic pain. Neurology 2005;65:437–43. Search in Google Scholar

[101] Robbins TW, Gillan CM, Smith DG, de Wit S, Ersche KD. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends Cogn Sci 2012;16:81–91. Search in Google Scholar

[102] Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636–45. Search in Google Scholar

[103] Tracey I. Can neuroimaging studies identify pain endophenotypes in humans? Nat Rev Neurol 2011;7:173–81. Search in Google Scholar

[104] Mayer EA, Aziz Q, Coen S, Kern M, Labus JS, Lane R, Kuo B, Naliboff B, Tracey I. Brain imaging approaches to the study of functional GI disorders: a Rome working team report. Neurogastroenterol Motil 2009;21:579–96. Search in Google Scholar

Received: 2013-12-31
Accepted: 2014-01-07
Published Online: 2014-04-01
Published in Print: 2014-04-01

© 2014 Scandinavian Association for the Study of Pain